NCT00529802View on ClinicalTrials.gov

Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

RAD001

take 2 tablets of RAD001 once a day by mouth (10 mg per day)

Trial Locations (5)

27599

The University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill

60637

University of Chicago, Chicago

61615

Oncology/Hematology Associates, Peoria

63110

Washington University, St Louis

02215

Beth Israel Deaconess Med Ctr, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Chicago

OTHER

NCT00529802 - Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer | Biotech Hunter | Biotech Hunter